Literature DB >> 24352810

Epidemiology of candidemia in Qatar, the Middle East: performance of MALDI-TOF MS for the identification of Candida species, species distribution, outcome, and susceptibility pattern.

S J Taj-Aldeen1, A Kolecka, R Boesten, A Alolaqi, M Almaslamani, P Chandra, J F Meis, T Boekhout.   

Abstract

INTRODUCTION: Bloodstream infections (BSIs) due to Candida spp. constitute the predominant group of hospital-based fungal infections worldwide. A retrospective study evaluated the performance of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) for the identification of BSI Candida isolates. The epidemiology, risk factors, demographic features, species distribution, and clinical outcome associated with candidemia in patients admitted to a single tertiary-care hospital in Qatar, were analyzed.
METHODS: A single-center, retrospective analysis covering the period from January 1, 2004 to December 31, 2010 was performed. Molecular identification used sequence analysis of the D1/D2 domains of the large subunit ribosomal DNA (LSU rDNA) and the ITS1/2 regions of the rDNA. MALDI-TOF MS-based identification of all yeast isolates was performed with the ethanol/formic acid extraction protocol according to Bruker Daltonics (Bremen, Germany). The susceptibility profiles of 201 isolates to amphotericin B, itraconazole, fluconazole, voriconazole, anidulafungin, caspofungin, posaconazole, and isavuconazole were tested using CLSI standard broth microdilution method (M27-A3 and M27 S4) guidelines. Statistical analyses were performed with the statistical package SPSS 19.0.
RESULTS: A total of 187 patients with 201 episodes of candidemia were identified. Candida albicans was the most common species isolated (33.8 %; n = 68), whereas non-albicans Candida species represented 66.2 % (n = 133) of the episodes. The species distribution and outcome of candidemia showed a difference in the crude mortality between patients infected with C. albicans (n = 30; 45.5 %) and non-albicans Candida species. For example, C. parapsilosis candidemia was associated with the lowest mortality rate (40.6 %), and patients with other non-albicans species had the highest mortality rate (68-71.4 %). High mortality rates were observed among pediatric (<1 year of age) and elderly patients (>60 years of age). All strains showed low minimum inhibitory concentrations (MICs) (MIC90 of 0.063 μg/ml) to isavuconazole. The overall resistance to voriconazole in vitro antifungal activity was 2.5 %. C. glabrata (n = 38) had an MIC90 of 8 μg/ml for fluconazole. Most yeast isolates were susceptible to anidulafungin (>99.5 %) and 81.1 % to caspofungin. Resistance to anidulafungin was detected in 1/8 (12.5 %) isolates of C. orthopsilosis. According to new Clinical and Laboratory Standards Institute (CLSI) breakpoints, C. glabrata (n = 38) showed 100 % resistance, and 37/68 (54.4 %) C. albicans isolates were susceptible dose dependent (SDD) to caspofungin. Identification by MALDI-TOF MS was in 100 % concordance with molecular identification.
CONCLUSION: The Middle East epidemiology of candidemia has a unique species distribution pattern distinct from other parts of the globe. High mortality rates were observed among pediatric (<1 year of age) and elderly patients (>60 years of age). All strains were susceptible to isavuconazole. All isolates of C.glabrata were resistant to caspofungin based on M27 S4. MALDI-TOF MS is a highly useful method for the routine identification of yeast isolates in clinical setting to achieve successful therapeutic treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24352810     DOI: 10.1007/s15010-013-0570-4

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  37 in total

1.  Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent?

Authors:  A Espinel-Ingroff; M C Arendrup; M A Pfaller; L X Bonfietti; B Bustamante; E Canton; E Chryssanthou; M Cuenca-Estrella; E Dannaoui; A Fothergill; J Fuller; P Gaustad; G M Gonzalez; J Guarro; C Lass-Flörl; S R Lockhart; J F Meis; C B Moore; L Ostrosky-Zeichner; T Pelaez; S R B S Pukinskas; G St-Germain; M W Szeszs; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2013-09-09       Impact factor: 5.191

2.  Candida glabrata fungemia: experience in a tertiary care center.

Authors:  Anurag Malani; Jareer Hmoud; Loretta Chiu; Peggy L Carver; Andrew Bielaczyc; Carol A Kauffman
Journal:  Clin Infect Dis       Date:  2005-08-24       Impact factor: 9.079

3.  Rare opportunistic (non-Candida, non-Cryptococcus) yeast bloodstream infections in patients with cancer.

Authors:  Maria N Chitasombat; Diamantis P Kofteridis; Ying Jiang; Jeffrey Tarrand; Russell E Lewis; Dimitrios P Kontoyiannis
Journal:  J Infect       Date:  2011-11-11       Impact factor: 6.072

4.  Distribution and epidemiology of Candida species causing fungemia at a Saudi Arabian hospital, 1996-2004.

Authors:  Jaffar A Al-Tawfiq
Journal:  Int J Infect Dis       Date:  2006-07-21       Impact factor: 3.623

5.  In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods.

Authors:  D J Diekema; S A Messer; L B Boyken; R J Hollis; J Kroeger; S Tendolkar; M A Pfaller
Journal:  J Clin Microbiol       Date:  2009-08-26       Impact factor: 5.948

6.  Epidemiology, presentation, management and outcome of candidemia in a tertiary care teaching hospital in the United Arab Emirates, 1995-2001.

Authors:  Michael Ellis; Ulla Hedstrom; Pauline Jumaa; Abdulbari Bener
Journal:  Med Mycol       Date:  2003-12       Impact factor: 4.076

7.  Epidemiologic and molecular characterization of an outbreak of Candida parapsilosis bloodstream infections in a community hospital.

Authors:  Thomas A Clark; Sally A Slavinski; Juliette Morgan; Timothy Lott; Beth A Arthington-Skaggs; Mary E Brandt; Risa M Webb; Mary Currier; Richard H Flowers; Scott K Fridkin; Rana A Hajjeh
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

8.  Prospective observational study of candidemia in São Paulo, Brazil: incidence rate, epidemiology, and predictors of mortality.

Authors:  Arnaldo L Colombo; Thaís Guimarães; Ligia R B F Silva; Leila Paula de Almeida Monfardini; Anna Karenine B Cunha; Patrícia Rady; Thelma Alves; Robert C Rosas
Journal:  Infect Control Hosp Epidemiol       Date:  2007-04-13       Impact factor: 3.254

9.  Candidemia by species of the Candida parapsilosis complex in children's hospital: prevalence, biofilm production and antifungal susceptibility.

Authors:  Luciana da Silva Ruiz; Sonia Khouri; Rosane Christine Hahn; Eriques Gonçalves da Silva; Vanessa Krummer Perinazzo de Oliveira; Rinaldo Ferreira Gandra; Claudete Rodrigues Paula
Journal:  Mycopathologia       Date:  2013-02-13       Impact factor: 2.574

10.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.

Authors:  Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

View more
  26 in total

1.  Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms.

Authors:  Dominique Sanglard; Alix T Coste
Journal:  Antimicrob Agents Chemother       Date:  2015-10-19       Impact factor: 5.191

2.  Update on fungal diagnostics.

Authors:  Allen T Griffin; Kimberly E Hanson
Journal:  Curr Infect Dis Rep       Date:  2014-08       Impact factor: 3.725

3.  Molecular Analysis of Resistance and Detection of Non-Wild-Type Strains Using Etest Epidemiological Cutoff Values for Amphotericin B and Echinocandins for Bloodstream Candida Infections from a Tertiary Hospital in Qatar.

Authors:  Saad J Taj-Aldeen; Husam Salah; Winder B Perez; Muna Almaslamani; Mary Motyl; Atqah AbdulWahab; Kelley R Healey; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

4.  Interlaboratory comparison of sample preparation methods, database expansions, and cutoff values for identification of yeasts by matrix-assisted laser desorption ionization-time of flight mass spectrometry using a yeast test panel.

Authors:  Anneloes Vlek; Anna Kolecka; Kantarawee Khayhan; Bart Theelen; Marizeth Groenewald; Edwin Boel; Teun Boekhout
Journal:  J Clin Microbiol       Date:  2014-06-11       Impact factor: 5.948

Review 5.  Mass spectrometry in research laboratories and clinical diagnostic: a new era in medical mycology.

Authors:  Hasti Kamali Sarvestani; Alireza Ramandi; Muhammad Ibrahim Getso; Taraneh Razavyoon; Javad Javidnia; Miaad Banay Golrizi; Ali-Akbar Saboor-Yaraghi; Saham Ansari
Journal:  Braz J Microbiol       Date:  2022-03-28       Impact factor: 2.214

6.  Candidaemia observed at a university hospital in Milan (northern Italy) and review of published studies from 2010 to 2014.

Authors:  Laura Milazzo; Anna Maria Peri; Cristina Mazzali; Romualdo Grande; Chiara Cazzani; Davide Ricaboni; Antonio Castelli; Ferdinando Raimondi; Carlo Magni; Massimo Galli; Spinello Antinori
Journal:  Mycopathologia       Date:  2014-07-24       Impact factor: 2.574

7.  Species distribution and susceptibility profile to fluconazole, voriconazole and MXP-4509 of 551 clinical yeast isolates from a Romanian multi-centre study.

Authors:  B Minea; V Nastasa; R F Moraru; A Kolecka; M M Flonta; I Marincu; A Man; F Toma; M Lupse; B Doroftei; N Marangoci; M Pinteala; T Boekhout; M Mares
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-09-16       Impact factor: 3.267

Review 8.  Recent trends in molecular diagnostics of yeast infections: from PCR to NGS.

Authors:  Toni Gabaldón
Journal:  FEMS Microbiol Rev       Date:  2019-09-01       Impact factor: 16.408

9.  Characterising atypical Candida albicans clinical isolates from six third-level hospitals in Bogotá, Colombia.

Authors:  Giovanni Rodríguez-Leguizamón; Alessandro Fiori; Luisa F López; Beatriz L Gómez; Claudia M Parra-Giraldo; Arley Gómez-López; Carlos F Suárez; Andrés Ceballos; Patrick Van Dijck; Manuel A Patarroyo
Journal:  BMC Microbiol       Date:  2015-10-05       Impact factor: 3.605

10.  Genome comparison of Candida orthopsilosis clinical strains reveals the existence of hybrids between two distinct subspecies.

Authors:  Leszek P Pryszcz; Tibor Németh; Attila Gácser; Toni Gabaldón
Journal:  Genome Biol Evol       Date:  2014-05       Impact factor: 3.416

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.